Diamyd Medical AB (DMYD B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Diamyd Medical AB (DMYD B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH1150415D
  • |
  • Pages: 59
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Diamyd Medical AB (Diamyd), formerly Diamyd Therapeutics AB is a drug development company that offers diabetes vaccine. The company's diabetes products include Diamyd, an antigen-based immunotherapy for the treatment of autoimmune diabetes. Its pipeline products include GAD, GABA, and other immunomodulatory agents. Diamyd's GABA or gamma-aminobutyric acid is synthesized from the amino acid glutamate in cells by the enzyme GAD which helps in the regulation of metabolism and the immune system. The company develops treatment for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technology. Diamyd is headquartered in Stockholm, Sweden.

Diamyd Medical AB (DMYD B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Diamyd Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Diamyd Medical AB, Medical Devices Deals, 2012 to YTD 2018 10

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Diamyd Medical Enters into Partnership with Cardiff University 12

Diamyd Medical Enters into Agreement with TFS Trial Form Support 13

Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 14

Licensing Agreements 15

Diamyd Medical Enters into Licensing Agreement with University of California 15

Diamyd Medical Enters into Licensing Agreement for Gliadin 16

Equity Offering 17

Diamyd Medical Raise USD10 Million in Rights Offering of Units 17

Diamyd Medical Raises USD2.6 Million in Rights Offering of shares 19

Diamyd Medical to Raise USD1.7 Million in Private Placement of Series B Shares 20

Acquisition 21

Diamyd Medical Acquires 16% Stake in NextCell Pharma 21

Diamyd Medical AB - Key Competitors 22

Diamyd Medical AB - Key Employees 23

Diamyd Medical AB - Locations And Subsidiaries 24

Head Office 24

Recent Developments 25

Financial Announcements 25

Oct 11, 2017: Diamyd Medical : Financial Statement 16/17 25

Apr 05, 2017: Diamyd Medical: Quarterly Report II 16/17 26

Jan 25, 2017: Diamyd Medical: Quarterly Report I 16/17 30

Corporate Communications 31

Jan 10, 2017: GABA-specialist to the Board of Diamyd Medical 31

Product News 32

07/27/2017: Additional Preliminary Interim Results From Intralymphatic Study with Diamyd Published as part of Scientific Correspondence in NEJM 32

07/06/2017: Interim Report From Diagnode-1 Supports Continued Positive Clinical Course After 15 Months 33

06/12/2017: Autoantigen GAD-Vaccine is Safe for Children at High Risk for Developing Type 1 Diabetes 34

06/09/2017: New interim report for Diamyd directly into the lymph node indicates continued positive clinical course 35

05/18/2018: Update regarding the manufacturing of Diamyd drug substance 36

05/07/2018: Results supporting intralymphatic administration of Diamyd published in the Journal of Diabetes Research 37

03/27/2017: 30 month results from DIABGAD-1 support effect after partial remission phase 38

03/12/2018: Interim report from DIAGNODE-1 shows continued positive clinical course 39

01/08/2018: The diabetes vaccine Diamyd shows continued positive clinical course after 30 months 40

01/05/2017: Last participant has completed last visit in a five-year prevention trial with Diamyd 41

Clinical Trials 43

Jul 04, 2018: The GABA/Diamyd trial in the US now fully recruited 43

Apr 23, 2018: 50% enrollment milestone reached in Diamyd Medical's European Phase II trial 44

Mar 02, 2018: Operational update on the diabetes vaccine Diamyd and recombinant GAD 45

Feb 22, 2018: The GABA/Diamyd trial in the US fully recruited this summer 46

Feb 09, 2018: High interest from patients to participate in the DIAGNODE-2 trial 47

Dec 11, 2017: The diabetes vaccine Diamyd shows positive results 48

Nov 13, 2017: Diamyd Medical: Phase II-trial DIAGNODE-2 ahead of World Diabetes Day now open to include patients 49

Oct 27, 2017: Diamyd Medical: Update concerning prevention studies with the diabetes vaccine Diamyd 50

Sep 27, 2017: Update on the strategic development of the study drug Remygen 51

Sep 21, 2017: Phase II trial DIAGNODE-2 with the diabetes vaccine Diamyd approved to start in all participating countries 52

May 22, 2017: Diamyd Medical submits application to the Medical Products Agency for the DIAGNODE-2 trial 53

May 19, 2017: Diamyd in combination with etanercept and vitamin D shows safety after six months 54

May 10, 2017: Article by Professor Johnny Ludvigsson on clinical trials with Diamyd published in Expert Opinion on Biological Therapy 55

Apr 21, 2017: Diamyd Medical enters agreement with global CRO for the DIAGNODE-2 trial 56

Mar 31, 2017: Swine influenza vaccination might have had an impact on treatment with the diabetes vaccine Diamyd in Phase III clinical trial 57

Feb 16, 2017: Previously announced preliminary interim results from intralymphatic study with Diamyd published in the New England Journal of Medicine 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59

List of Figures

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Diamyd Medical AB, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Diamyd Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Diamyd Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Diamyd Medical AB, Deals By Therapy Area, 2012 to YTD 2018 9

Diamyd Medical AB, Medical Devices Deals, 2012 to YTD 2018 10

Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Diamyd Medical Enters into Partnership with Cardiff University 12

Diamyd Medical Enters into Agreement with TFS Trial Form Support 13

Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 14

Diamyd Medical Enters into Licensing Agreement with University of California 15

Diamyd Medical Enters into Licensing Agreement for Gliadin 16

Diamyd Medical Raise USD10 Million in Rights Offering of Units 17

Diamyd Medical Raises USD2.6 Million in Rights Offering of shares 19

Diamyd Medical to Raise USD1.7 Million in Private Placement of Series B Shares 20

Diamyd Medical Acquires 16% Stake in NextCell Pharma 21

Diamyd Medical AB, Key Competitors 22

Diamyd Medical AB, Key Employees 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Diamyd Medical AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 17970
Site License
USD 500 INR 35940
Corporate User License
USD 750 INR 53910

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com